[1-[(3-Aminopyridin-4-yl)methyl]piperidin-4-yl]-[4-(2,3-dihydroindol-1-yl)piperidin-1-yl]methanone | 639506-36-8

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: [1-[(3-Aminopyridin-4-yl)methyl]piperidin-4-yl]-[4-(2,3-dihydroindol-1-yl)piperidin-1-yl]methanone
• CAS: 639506-36-8
• 化学式: C₂₅H₃₃N₅O
• 分子量: 419.57
• InChiKey: ZAAVXRLHQLPXKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  65.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Indole derivatives useful as histamine H3 antagonists
  申请人：SCHERING CORPORATION

  公开号：EP1777223A1

  公开（公告）日：2007-04-25

  Disclosed are novel compounds of the formula I wherein M1 is CH or N and M2 is C(R3) or N; R1 is optionally substituted indolyl or an aza derivative thereof; R2 is optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are the uses of the compounds of formula I for treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion). Also disclosed are uses of the compounds of formula I in combination with a H1 receptor antagonist for treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion).

  公开了式 I 的新型化合物，其中 M1 是 CH 或 N，M2 是 C(R3) 或 N；R1 是任选取代的吲哚基或其氮杂衍生物；R2 是任选取代的芳基或杂芳基；其余变量如说明书中所定义。还公开了包含式 I 化合物的药物组合物。还公开了式 I 化合物用于治疗各种疾病或病症的用途，例如过敏、过敏引起的气道反应和鼻塞（如鼻塞）。还公开了式 I 化合物与 H1 受体拮抗剂结合用于治疗各种疾病或病症的用途，例如过敏、过敏引起的气道反应和充血（如鼻塞）。
• [EN] COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT<br/>[FR] COMBINAISON D'UN ANTAGONISTE/AGONISTE INVERSE DE H3 ET D'UN MODERATEUR DE L'APPETIT
  申请人：SCHERING CORP

  公开号：WO2007075555A2

  公开（公告）日：2007-07-05

  [EN] The present invention relates to pharmaceutical compositions comprising therapeutic combinations comprising: one or more H3 antagonists/inverse agonists; one or more appetite suppressants selected from the group consisting of CBi antagonists/inverse agonists, sibutramine, phentermine and topiramate; and option one or more HMG-CoA reductase inhibitors. The invention also relates to medicaments and kits comprising the pharmaceutical compositions of the present invention, and methods of treating obesity, obesity related disorders and diabetes using the pharmaceutical compositions of the present invention.
  [FR] La présente invention concerne des compositions pharmaceutiques comprenant les combinaisons thérapeutiques suivantes : un ou plusieurs antagonistes/agonistes inverses de H3 ; un ou plusieurs modérateurs de l'appétit choisis dans le groupe comprenant des antagonistes/agonistes inverses de CBi, la sibutramine, la phentermine et le topiramate ; et facultativement un ou plusieurs inhibiteurs de la HMG-CoA réductase. L'invention concerne également des médicaments et des kits comprenant les compositions pharmaceutiques de la présente invention et des procédés de traitement de l'obésité, des troubles liés à l'obésité et du diabète à l'aide des compositions pharmaceutiques de la présente invention.